RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue51,4952,612133-
Cost of Revenue295,144231,645183,204114,737
Gross Profit-243,649-229,033-183,071-114,737
Operating Expenses
Research Development293,998293,998293,998293,998
Selling General and Administrative127,72493,90964,93633,001
Non Recurring----
Others----
Total Operating Expenses422,868325,554248,140147,738
Operating Income or Loss-371,373-322,942-248,007-147,738
Income from Continuing Operations
Total Other Income/Expenses Net174,2764,6042,1682,120
Earnings Before Interest and Taxes-371,373-322,942-248,007-147,738
Interest Expense----
Income Before Tax-197,097-318,338-245,839-145,618
Income Tax Expense514-16,19935-
Minority Interest----
Net Income From Continuing Ops-197,611-302,139-245,874-145,618
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-197,611-302,139-245,874-145,618
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-197,611-302,139-245,874-145,618